Savid Therapeutics Inc.

Tomohiro Meshizuka

Tsuyoshi Inoue

Akira Sugiyama

Tatsuhiko Kodama

Motomu Kanai

Hirofumi Doi

Yohei Shimizu

Eiichi Mizohata

Tatsuya Kawato

Mari Takatsu

Noriaki Takasu

Tomohiro Yamamoto

An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, and usage of them.

Modified biotin, streptavidin mutant, and usage of them

An object of this invention is to provide a streptavidin mutant reduced in affinity to the naturally-occurring biotin, and to provide a modified biotin which shows a high affinity to such streptavidin mutant reduced in affinity to the naturally-occurring biotin. This invention can provide a compound composed of a dimer of modified biotin, a streptavidin mutant, angsd usage of them.

It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.

Modified biotin, mutant streptavidin, and use thereof

Growing community of inventors

Osaka, Japan

Tomohiro Meshizuka